MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. [NYSE: MDT] announced today that it has provided a grant to Yale University to conduct two fully independent, third-party systematic reviews of the safety and effectiveness of its recombinant bone morphogenic protein-2 (rhBMP-2) product, which stimulates bone formation.
